|
| |
Matrix Laboratories LimitedMatrix Laboratories Limited is a public limited company listed on the major stock exchanges in India and is engaged in the manufacture of Active Pharmaceutical Ingredients (APIs) and Solid Oral Dosage Forms. The development and manufacture of quality intermediates, bulk actives have been critical to our success in delivering innovative and affordable products for both the domestic as well as international markets.
With about 2000 employees, including over 200 R&D scientists, Matrix conducts research & development, and manufacture products at the company's cGMP facilities located near Hyderabad and Visakhapatnam, India. The company's Solid Oral Dosage Forms facility is located near Nashik, about 150 km from Mumbai
| Contact Details: |
| 1-1-151/1, 4th FloorSai Ram Towers
Alexander Road |
| Secunderabad |
| Andhra Pradesh |
| 500 003 |
| India |
| Tel: | 91-40-27700363 |
| Fax: | 91-40-27700343 |
| Email: | matrix@matrixlabsindia.com |
| WWW: | www.matrixlabsindia.com/
|
| |
Recent Publications by Matrix Laboratories Limited: |  |
Recent advances in glucokinase activators for the treatment of type 2 diabetes.
Glucokinase is a member of the hexokinase family of enzymes that are... | 21st October, 2009
| New Drug Discovery, Matrix Laboratories Limited, Anrich Industrial Estate,
| Drug Discov Today. 2009 Aug;14(15-16):784-92. Epub 2009 Jun 9.
DOI Direct Link |
Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes.
Emerging as an epidemic of the 21st century type 2 diabetes has become a... | 30th May, 2009
| New Drug Discovery, Matrix Laboratories Limited, Anrich Industrial Estate,
| Bioorg Med Chem. 2009 Mar 1;17(5):1783-802. Epub 2009 Jan 31.
DOI Direct Link |
Vanilloid receptor antagonists: emerging class of novel anti-inflammatory agents for pain management.
Neuropathic pain affects 26 million patients worldwide resulting in a... | 19th May, 2009
| New Drug Discovery, R & D Center, Matrix Laboratories Limited, Anrich
| Curr Pharm Des. 2009;15(9):1008-26.
|
Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes.
Dipeptidyl peptidase IV (DPP IV) is a key regulator of insulin-stimulating... | 28th March, 2009
| New Drug Discovery, R & D Center, Matrix Laboratories Limited, Anrich
| Curr Drug Targets. 2009 Jan;10(1):71-87.
|
Synthesis of imidazol-1-yl-acetic acid hydrochloride: A key intermediate for zoledronic acid.
A convenient and practical synthesis of imidazol-1-yl-acetic acid... | 24th December, 2008
| New Drug Discovery, Matrix Laboratories Limited, Anrich Industrial Estate,
| Beilstein J Org Chem. 2008;4:42. Epub 2008 Nov 17.
DOI Direct Link |
→View more Matrix Laboratories Limited research publications. |
Press Releases on Matrix Laboratories Limited:
|
 |
| Mylan Receives FDA Approval for Generic Version of Prevacid(R) Through its Subsidiary Matrix Laboratories |
10th November, 2009 |
Mylan Inc. |
PITTSBURGH, Nov. 10 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its privately held Indian subsidiary, Matrix Laboratories Limited, has received final approval from the U.S.
|
| Mylan Reports Third Quarter Adjusted Diluted EPS of $0.32 |
29th October, 2009 |
Mylan Inc. |
-- On a GAAP basis, earnings per diluted share of $0.29 for the nine months
ended September 30, 2009.
Mylan's Chairman and CEO Robert J. Coury commented: "I am particularly
|
| Mylan Announces Successful Matrix Delisting Offer |
1st June, 2009 |
Mylan Inc. |
PITTSBURGH, June 1 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its wholly-owned subsidiary, MP Laboratories (Mauritius) Ltd, has completed its delisting offer for the
|
| Mylan's Matrix Selected by the Clinton HIV/AIDS Initiative and UNITAID as the Primary Supplier of Five Second-Line and Seven Pediatric HIV/AIDS Treatments |
20th April, 2009 |
Mylan Inc. |
PITTSBURGH, April 20 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that Matrix Laboratories Limited, its India-based subsidiary in which it holds a 71.2% controlling interest, has
|
| Mylan's Matrix Receives First Tentative FDA Approval Under PEPFAR for Generic Truvada(R) |
30th March, 2009 |
Mylan Inc. |
PITTSBURGH, March 30 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that Matrix Laboratories Limited, its India-based subsidiary in which it holds a 71.2% controlling interest, has
|
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 926 times since April 2007, the link to the organisation's website has been followed 127 times Recent Search Terms used to find this page: projects offering in matrix lab vizag | matrix mylan gabapentin | MATRIX LABORATORIES LTD offer results | synthesis of zoledronic | MP LABORATORIES (MAURITIUS) LTD | zoledronic acid Indian manufacturer | matrix laboratories contact, visakhapatnam | matrix laboratories pittsburgh | matrix lab | process for the preparation of gabapentin | . Search for more companies in Secunderabad Search for more companies in Andhra Pradesh This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Matrix Laboratories Limited |
